BAY 1214784, a potent, selective, and orally active spiroindoline derivative compound, serves as an antagonist of the human gonadotropin-releasing hormone receptor (hGnRH-R). It notably reduces plasma luteinizing hormone levels by up to 49%, demonstrating low pharmacokinetic variability and good tolerability. This compound shows promise for research into uterine fibroids.